Dr. James Berenson is the medical and scientific director, as well as the chief executive officer of Oncotherapeutics and the Institute for Myeloma and Bone Cancer Research (IMBCR). He also has his private practice located in West Hollywood, California. He serves on the Scientific Boards of the Multiple Myeloma Research Foundation and the International Myeloma Foundation, as well as working with many other groups known for their work in multiple myeloma and bone metastases.

After earning his doctorate in medicine from the University of California at San Diego, Dr. Berenson completed his internship and residency in internal medicine at the University of Utah Medical Center and his fellowships in hematology/oncology at the University of California at Los Angeles (UCLA). He is certified by the American Board of Internal Medicine in both internal medicine and medical oncology. 

Faculty Disclosure
Dr. James Berenson has received grant support related to research activities from Novartis AG, Celgene Corporation, Cephalon, Inc., Millennium Pharmaceuticals, Inc., Amgen Inc., CuraGen Corporation, Cytogen, Seattle Geriatrics, Pfizer Inc., and ZIOPHARM Oncology, Inc. He has received honoraria related to speakers’ bureau activities from Novartis, Celgene, Cephalon, Millennium, and Ortho Biotech Products, L.P., as well as consultant fees from Novartis, Celgene, Cephalon, Millennium, Ortho Biotech, Amgen, CuraGen, Cytogen, and Seattle Geriatrics.